CD274 and neoplasm: When the outcomes of all animals were taken into account, the overall therapeutic efficacy of MYXV treatment correlated strongly with the percentage of PDL1 capable cells found in a tumor at the time of treatment with 1:1 chimeric tumors responding better then fully PDL1 capable tumors but not as well as 1:9 chimeric tumors (Figs 2a - c).